Search

Your search keyword '"Zanaboni, Laura"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Zanaboni, Laura" Remove constraint Author: "Zanaboni, Laura"
30 results on '"Zanaboni, Laura"'

Search Results

1. Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins

6. Growth hormone deficiency (GHD) in adult thalassaemic patients

7. Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone

8. Human CD34+ Cells from Different Sources Disclose a Specific Stemness Signature

9. Intrinsic Molecular Features of Human Hematopoietic Stem Cells from Different Sources Define Their Specific Functional Properties

11. Prevalence of hypothyroidism in a large series of adult thalassemic patients

12. The Challenge Of HSCs Procurement For Gene Therapy: Exploring Plerixafor As Mobilization Agent

13. Plerixafor Single Agent for Autologous Stem Cells Mobilization and Collection in Adult Thalassemic Patients: Towards the Assessment of the Suitable Hematopoietic Stem Cell Source for Gene Therapy of Beta-Thalassemia.

18. Neridronate (NE) for the Treatment of Osteoporosis In Patients with β-Thalassemia: Results from an Italian Multicenter Randomized, Open Label, Phase II Trial

20. The pituitary–adrenal axis in adult thalassaemic patients

25. Human CD34+Cells from Different Sources Disclose a Specific Stemness Signature

26. Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to Plerixafor alone

27. Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone.

28. An update on iron chelation therapy.

29. Pregnant women affected by thalassemia major: a controlled study of traits and personality.

30. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Catalog

Books, media, physical & digital resources